State of the art biological therapies in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDA...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:World J Gastrointest Oncol
Asıl Yazarlar: Di Marco, Mariacristina, Grassi, Elisa, Durante, Sandra, Vecchiarelli, Silvia, Palloni, Andrea, Macchini, Marina, Casadei, Riccardo, Ricci, Claudio, Panzacchi, Riccardo, Santini, Donatella, Biasco, Guido
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Baishideng Publishing Group Inc 2016
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4714146/
https://ncbi.nlm.nih.gov/pubmed/26798437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v8.i1.55
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller